Shots:

• JAMP Pharma to get exclusive commercialization rights for Alvotech’s five biosimilars in Canada. Alvotech will take care of full development and commercial supply of the biosimilars from their new state-of-the-art manufacturing facility in Reykjavik- Iceland
• The focus of the agreement is to strengthen and expand the footprints of JAMP’s generic which is expected to surpass 500 products by 2022 plus Alvotech’s biosimilar portfolio in the Canadian market
• Alvotech presently contains 7 biosimilars targeted to treat multiple immune and inflammatory conditions- oncology and ophthalmology. Additionally- the current market value of these biosimilars is estimated to exceed $2B annually

Click here to read full press release/ article | Ref: Alvotech | Image: Behance